This is the authors' abstract. We don't add key points for this paper.
RYGB demonstrates higher efficacy for T2DM remission compared to SG, regardless of baseline characteristics, T2DM severity, weight loss, and follow-up duration. Further studies are needed to understand the long-term metabolic effects of MBS and the underlying pathophysiology of T2DM remission after MBS.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Hage et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: